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Abstract
Introduction: Collagen is a widely used naturally occurring biomaterial for scaffolding, whereas mesenchymal stem
cells (MSCs) represent a promising cell source in tissue engineering and regenerative medicine. It is generally
known that cells are able to remodel their environment by simultaneous degradation of the scaffolds and
deposition of newly synthesized extracellular matrix. Nevertheless, the interactions between MSCs and collagen
biomaterials are poorly known, and the strategies enhancing the extracellular matrix deposition are yet to be
defined. In this study, we aim to investigate the fate of collagen when it is in contact with MSCs and hypothesize
that protease inhibition will enhance their extracellular deposition of collagen fibrils.
Methods: Specifically, human MSCs (hMSCs) were exposed to fluorescence-labeled collagen with and without
intracellular or extracellular protease inhibitors (or both) before tracing the collagen at both intracellular and
extracellular spaces.
Results: Collagen were internalized by hMSCs and degraded intracellularly in lysosomes. In the presence of
protease inhibitors, both intracellular collagen fibril growth and extracellular deposition of collagen fibrils were
enhanced. Moreover, protease inhibitors work synergistically with ascorbic acid, a well-known matrix
deposition-enhancing reagent, in further enhancing collagen fibril deposition at the extracellular space.
Conclusion: These findings provide a better understanding of the interactions between hMSCs and collagen
biomaterials and suggest a method to manipulate matrix remodeling and deposition of hMSCs, contributing to
better scaffolding for tissue engineering and regenerative medicine.
Keywords: Protease inhibitor, Collagen fibril deposition, Matrix remodeling, Mesenchymal stem cells, Collagen,
Intracellular, Extracellular
Introduction
Collagen represents one of the major components of
extracellular matrix (ECM) in mammalian tissues. It has
been widely used as a naturally occurring biomaterial in
tissue engineering and regenerative medicine because of
its excellent biocompatibility, negligible immunogenicity,
specific interaction with growth factors and cell adhesion
molecules, biodegradability, and the fact that it permits
cell ingrowth and matrix remodeling [1]. Collagen is a
biomacromolecule with triple-helical peptide. When
present at a concentration higher than the threshold
(e.g., 25 μg/ml) with appropriate temperature, pH, and
ionic strength, collagen molecules would self-assemble
to form collagen meshwork, mimicking that in the ECM
of the native tissues. We previously developed a scaffold-
ing technology platform, namely collagen microencapsula-
tion [2], which entraps living cells such as mesenchymal
stem cells (MSCs) [2], chondrocytes [3], and nucleus pul-
posus cells [4].
MSCs represent promising cell sources for tissue en-
gineering and regenerative medicine because of their
multiple differentiation potential, self-renewal capability,
easy accessibility, and hypo-immunogenic nature [5–8].
Previous studies demonstrated that MSCs adhered,
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proliferated, and differentiated on collagen via integrins
and ERK activation [9–11]. Our own work showed that
human MSCs (hMSCs) are able to express integrins
α2β1, α5β1, and αvβ3 in the collagen matrix environ-
ment [12].
The ECM niche is a complex network of topograph-
ical, mechanical, and biochemical factors regulating
cellular-fate processes, including cell proliferation, differ-
entiation, shape, and migration [13–16]. Matrix metallo-
proteinases (MMPs) that cleave the protein components
of the ECM as well as non-ECM molecules play a central
role in matrix remodeling [17]. Several studies demon-
strated that MMPs are involved in migration, proliferation,
and differentiation of MSCs [18–20]. Moreover, cysteine
proteases are involved in ECM remodeling as demon-
strated in bone resorption, wound healing, and arterial re-
modeling [21]. In this study, we hypothesize that inhibiting
intracellular and extracellular proteases will affect the
matrix remodeling, including collagen fibril deposition of
MSCs. Specifically, we aim to study how collagen matrix
material interacts with MSCs, including collagen internal-
ization and degradation as well as the effect of intracellular
and extracellular protease inhibitors on collagen fibril de-
position. This study provides a better understanding of the
interactions between cells and collagen matrix and sug-
gests a method to promote ECM meshwork deposition of
hMSCs, contributing to rationalized scaffolding for tissue
engineering and regenerative medicine.
Methods
2D monolayer culture of human mesenchymal stem cells
hMSCs from bone marrow were kindly provided by
G.C.F. Chan, of the Department of Paediatrics and Ado-
lescent Medicine, the University of Hong Kong, and cul-
tured as monolayers as previously described [22]. All
procedures were approved by the Combined Clinical
Ethics Committee of the University of Hong Kong and
Hong Kong West Cluster Hospitals of Hospital Authority.
In brief, hMSCs were cultured in growth medium—
Dulbecco’s modified Eagle’s medium-low glucose
(DMEM-LG), 10 % fetal bovine serum, 100 U/ml penicil-
lin, 100 mg/ml strepto-mycin and 2 mM L-glutamine—at
37 °C in a humidified atmosphere with 5 % CO2. The
growth medium was replaced every 3–4 days. At around
80 % confluence, hMSCs were trysinized with trypsin-
EDTA (0.05 %) before re-suspending in full medium for
subsequent experiments. Cells at P6 were used for subse-
quent experiments.
Collagen internalization and degradation in hMSC
monolayer culture
To study whether hMSCs in monolayer cultures would
internalize the exogenously supplemented collagen matrix,
rat tail type I collagen (BD Biosciences, Bedford, MA,
USA) was fluorescently labeled before exposure to hMSC
cultures, as previously described [23]. In brief, type I colla-
gen solution in 0.02 N acetic acid was re-suspended in
2 mM HCl after salting out with 0.9 M NaCl. Then pH of
the type I collagen solution in 2 mM HCl was raised by
sodium carbonate buffer (0.5 M NaCl and 0.1 M sodium
carbonate) to pH of 7.5 to approximately 8.3. Alexa Fluor
488 or Alexa Fluor 647 carboxylic acid succinimidyl ester
(Invitrogen, part of Thermo Fisher Scientific, Waltham,
MA, USA) was transferred to collagen solution and incu-
bated at room temperature for 30 min. Labeling reaction
was stopped by lowering pH, and the labeled collagen was
purified by salt precipitation and dialysis against
0.02 N acetic acid extensively. The concentration of
the fluorescence-labeled collagen was then determined
by a Circular Dichroism machine at 221 nm (lambda
spectrum; PerkinElmer, Waltham, MA, USA). Serum-
free culture medium (DMEM-LG medium with 1 %
penicillin-streptomycin and 1 % L-glutamine) contain-
ing the fluorescently labeled collagen at a concentra-
tion of 25 μg/ml was freshly prepared at 4 °C. hMSCs
were then incubated with the collagen-containing
serum-free medium for up to 24 h before inspection for
internalized collagen under confocal laser scanning fluor-
escence microscopy (LSM710; Carl Zeiss, Oberkochen,
Germany). In separate batches of experiments, DQ FITC-
labeled collagen (1 %) (Life Technologies, Carlsbad, CA,
USA), which fluoresces if degraded, was used to incubate
with hMSC monolayer cultures for 24 h to study whether
the internalized collagen was degraded by the cells.
3D microencapsulation of hMSCs in type I collagen
To study whether extracellular collagen matrix can be
internalized by hMSCs when the cells are exposed to the
matrix in three-dimensional (3D) configuration, hMSCs
were microencapsulated in collagen as previously reported
[2]. hMSCs were mixed with 1 % FITC-labeled bovine type
I collagen solution (Life Technologies) in an ice bath with a
cell seeding density of 1 × 105 or 5 × 105 cells/ml and a col-
lagen concentration of 1 or 2 mg/ml. Tiny droplets of the
mixtures (2.5 μl) were pipetted into petri dishes, the bot-
toms of which were covered with parafilm to prevent adhe-
sion of the constructs to the substratum. The collagen-
hMSC mixtures were gelated when incubated at 37 °C in a
humidified atmosphere with 5 % CO2 for 45 min. The gel-
ated droplets were then free-floated in growth medium to
allow contraction before harvesting at different time points
(3, 19, and 23 h) for inspection of the internalized collagen.
Inhibition of collagen degradation using protease
inhibitors and enhancing collagen synthesis by ascorbic
acid in hMSCs
Glass coverslips (10 mm in diameter) were placed into a
4- or 24-well plate and sterilized with 70 % ethanol and
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ultraviolet irradiation. hMSCs were then seeded on the
glass coverslips at a density of 1 × 104 per well and
cultured for overnight. The cells were washed with
phosphate-buffered saline (PBS) and serum-free
medium. After incubation for 1 h in serum-free medium,
medium was replaced with serum-free medium contain-
ing fluorescently labeled type I collagen at a concentra-
tion of 10 μg/ml. Cells were moved to 37 °C in a
humidified atmosphere with 5 % CO2 for the desired
time periods (4, 24, 48, and 72 h). To study the effects of
inhibiting matrix degradation on ECM deposition, the
free collagen present in the serum-free medium was la-
beled with Alexa Fluor 488 such that when matrix is de-
posited, fluorescence fibrils would be observed. To
inhibit collagen degradation, an intracellular matrix deg-
radation inhibitor, namely E64D (20 mM), or a broad-
spectrum ECM degradation inhibitor, namely GM6001
(25 mM) was previously optimized, or the combination
of both inhibitors was supplemented to hMSCs in
serum-free medium. To enhance collagen synthesis by
hMSCs, 0.5 mM of ascorbic acid (Sigma-Aldrich, St.
Louis, MO, USA) was supplemented in culture medium
either in serum-free medium or in medium with serum.
To visualize intracellular collagen, extracellular collagen
and collagen fibrils were removed by bacterial collage-
nase (50 units/ml) for 10 min. At appropriate time
points, incubation was terminated by rinsing in PBS and
fixing with 4 % paraformaldehyde for 10 min at room
temperature before subsequent immunofluorescence
evaluation.
Fluorescence or immunofluorescence evaluation
Exogenously supplemented collagen was fluorescence-
labeled either by Alexa 488 or similar fluorescence
probes as previously demonstrated [23] or by DQ-FITC
labeled collagen, which becomes fluorescent when being
degraded. Newly synthesized type I collagen by hMSCs
was evaluated by immunofluoresence. Specifically, sam-
ples were fixed with 4 % PBS-buffered paraformaldehyde
for 10 min at room temperature. Fixed samples were
permeabilized by 0.02 % Triton X-100 (Sigma-Aldrich)
for 10 min at room temperature in the dark. Endogen-
ous peroxidase activity was blocked with H2O2. Samples
were blocked with 2 % normal horse serum for non-
specific binding and then incubated with a primary anti-
body against human type I collagen (rat anti-human type
I collagen antibody in 1:200 dilution; Chondrex, Redmond,
WA, USA) overnight at 4 °C. Samples were further incu-
bated with Alexa Fluor 488- or 647-conjugated secondary
antibody in the dark for 1 h at room temperature. Samples
were washed with PBST (PBS with 0.05 % Tween20) for
5 min four times and then mounted with anti-fading fluor-
escent mounting medium with 4ʹ,6-diamidino-2-phenylin-
dole (DAPI) (Electron Microscopy Sciences, Hatfield, PA,
USA). Some subcellular organelles were labeled to provide
the reference for intracellular location. To visualize lyso-
somes, which are the organelles that internalize collagen,
50 nM LysoTracker (Molecular Probe, 1:1000) was added
to the culture medium for 60 min at 37 °C prior to fixation
with 4 % paraformaldehyde. To visualize cell membrane,
CellMask Red (Life Technologies, 2.5 mg/ml) was added
to the culture medium for 8 min after the lysotracker la-
beling. DAPI was used to label the nuclei.
Quantitative analysis of internalized collagen and
extracellularly deposited collagen fibrils
To analyze the amount of collagen internalized in the
intracellular space or deposited in the extracellular space
quantitatively, hMSCs were incubated with culture
medium containing fluorescently labeled collagen mono-
mers for various period of time. Quantitative analysis of
internalized Alexa 488-labeled collagen was determined
by measuring the total fluorescence, using a microplate
reader (Safire II; Tecan, San Jose, CA, USA), in the cell
lysate fraction collected up to 50 h after discarding the
extracellular fraction containing deposited collagen fi-
brils by digestion with excess bacterial collagenase
(Sigma-Aldrich). In separate experiments, after discard-
ing the culture medium, the collagen fibrils deposited in
the extracellular space were digested by collagenase, and
the amount of collagen was determined by measuring
the total fluorescence in this fraction.
Data presentation and statistics
Quantitative data on the percentage of collagen content
were presented as mean and standard error of the mean.
The normality assumption was verified with the
Kolmogorov-Smirnov test and the equal variance as-
sumption was verified by Levene’s test to justify the use
of parametric tests. The collagen content among differ-
ent treatment groups at different time points was com-
pared by using two-way analysis of variance (ANOVA)
with appropriate post hoc tests. For data with equal vari-
ance assumed, Bonferroni’s test was used. For data with-
out equal variances, Dunnett’s T3 test was used. SPSS
19.0 (IBM Corporation, Armonk, NY, USA) was used to
execute all analyses, and the statistical significance was
set at 0.05.
Results
Collagen was internalized and degraded by hMSCs in
both 2D and 3D models
Figure 1a-c showed the presence of fluorescence (Alexa
488)-labeled collagen inside the human MSCs as soon as
1 h after incubation with serum-free culture medium
containing collagen. The internalized collagen was de-
graded as shown by the presence of fluorescence stain-
ing of fluorescein-conjugated DQ-collagen (Fig. 1d),
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which becomes fluorescent only when collagen is being
degraded. Moreover, the degrading collagen also co-
localized (Fig. 1f ) with lysosomes (Fig. 1e), which are the
subcellular organelles responsible for internalizing mole-
cules, at 24 h after incubation. In a 3D collagen micro-
encapsulation model, internalization of collagen was also
demonstrated (Fig. 1g-i). Specifically, Fig. 1g showed that
internalization of fluorescence-labeled collagen was
noted as early as 3 h after encapsulation. Figure 1h
showed the image projection of an MSC-collagen micro-
sphere in which hMSCs were labeled with lysosomes
and randomly distributed in fluorescence-labeled colla-
gen meshwork, at 19 h after encapsulation. Figure 1i
showed a magnified view of a single hMSC in the 3D
collagen microsphere at 23 h after encapsulation where
the yellowish co-localization of the lysosome and the
fluorescence-labeled collagen was obvious. Figure 1i1
and i2 showed the side views of the cell where the
fluorescence-labeled collagen co-localized with lyso-
somes in the cytoplasm within the same cell, demon-
strating intracellular internalization.
Protease inhibitors enhanced the deposition of collagen
fibrils at the extracellular space
In addition to internalizing and degrading the exogen-
ously supplemented collagen monomers, hMSCs
organize and form thick and long collagen fibrils at
extracellular space, as shown by the green fluorescent
collagen fibrils, as soon as 4 h after incubation (Fig. 2a),
and it was more obvious at 24 h (Fig. 2e) in the control
Fig. 1 Collagen internalization and degradation by hMSCs (P6). a-f Two-dimensional monolayer culture: a-c 1-hour incubation in serum-free
medium (green: Alexa Fluor 488 labeled collagen; 25 μg/ml; blue: nucleus labeled by DAPI); d-f 24-hour incubation in serum-free medium where
DQ FITC-labeled collagen was 10 % of total collagen content (20 μg/ml) (green: fluorescein-conjugated DQ-collagen type I; red: lysosomes). g-i
Three-dimensional culture in collagen microspheres at different time points: g 2 mg/ml type I rat collagen with cell density at 1 × 105 per ml at
3 h after encapsulation; h 1 mg/ml type I rat collagen with cell density at 5 × 105 per ml at 19 h after encapsulation; i 1 mg/ml type I rat collagen
with cell density at 5 × 105 per ml at 23 h after encapsulation; i1 and i2 Side views of hMSCs inside a collagen microsphere (green: 1 %
fluorescein-labeled bovine collagen; red: LysoTracker-labeled cell). DAPI 4ʹ,6-diamidino-2-phenylindole, FITC fluorescein isothiocyanate, hMSC
human mesenchymal stem cell
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Fig. 2 Extracellular collagen fibril formation by hMSCs in different treatment groups at different time points. a-d 4 h. e-h 24 h. i-l 48 h. m-p 72 h.
q-t Day 11. a, e, i, m, q Control (normal medium). b, f, j, n, r Inhibition of intracellular matrix degradation by intracellular cysteine proteinase
inhibitor E64D. c, g, k, o, s Inhibition of extracellular matrix degradation by wide range collagenase inhibitor GM6001. d, h, l, p, t Inhibition of
both intracellular and extracellular matrix degradation. E64D (20 μM); GM6001 (25 μM); green: Alexa Fluor 488-labeled collagen type I at 10 μg/ml;
orange: Lysosomes. u Quantitative analysis of percentage of collagen content in extracellular fibril fraction under different treatments and at
different time points (n = 2 with duplicates). hMSC human mesenchymal stem cell
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group. Thicker and longer collagen fibrils were continu-
ously formed at 48 and 72 h after incubation (Fig. 2i, m).
With presence of protease inhibitors (Fig. 2b-d, f-h, j-l,
n-p), there is an obvious trend of enhanced collagen fi-
bril formation at the extracellular space. Specifically, in
the presence of intracellular protease inhibitor, there was
a slight increase in the extracellular collagen fibril for-
mation (Fig. 2b, f, j, n) as compared with the control
group. With the presence of extracellular collagenase in-
hibitor, extensive deposition of collagen meshwork at the
extracellular space was noted (Fig. 2c, d, g, h, k, l, o, p)
and was particularly obvious at 48 (Fig. 2k, l) and 72
(Fig. 2o, p) hours after incubation. On day 11, extensive
accumulation of thick collagen bundles at the extracellu-
lar space was noted in the presence of extracellular pro-
tease inhibitor (Fig. 2s, t). In separate experiments,
quantitatively analyzing the amount of collagen depos-
ited at the extracellular space after collagenase digestion
at 4 and 24 h after exposure of hMSCs to exogenously
supplemented collagen monomers was shown in Fig. 2u.
There was an overall increasing trend of extracellularly
deposited collagen fibrils. At 4 h, 12 % of collagen was
deposited as fibrils in the extracellular protease inhibitor
(GM6001) group, but only less than 6 % of extracellu-
larly deposited collagen was found in other groups, in-
cluding the control and the groups with intracellular
protease inhibitor (ED64). At 24 h, collagen fibril depos-
ition was significantly increased in all groups that those
treated with extracellular protease inhibitors (GM6001
alone and a combination of both ED64 and GM6001)
showed more than 70 % collagen in the deposited fibril
fraction. On the other hand, the group treated with
intracellular protease inhibitor (ED64) showed approxi-
mately 60 % collagen in the deposited fibril fraction as
compared with less than 50 % in the control group.
Two-way ANOVA showed that both the treatment
group (P < 0.001) and the time factor (P < 0.001) signifi-
cantly affected collagen deposition. Bonferroni’s post hoc
tests showed that all groups were significantly different
from one another (P ≤ 0.003).
Extracellular protease inhibitors promoted intracellular
collagen fibril formation and growth without changing
the total collagen internalized
To visualize the collagen fibril formation and growth in
the intracellular space, hMSCs were continuously treated
with collagenase, which removes the extracellularly de-
posited collagen. Figure 3 showed the presence of colla-
gen fibrils in the intracellular space of hMSCs at
different time points followed by collagenase treatment.
There was not much collagen fibril at 2 h in most
groups (Fig. 3a-c), but some short fibrils were noted in
the group with extracellular protease inhibitor (Fig. 3d).
At 4 h, more collagen was observed within the
intracellular space in all groups (Fig. 3e-h), although
long collagen fibrils were observed at the intracellular
space only in groups treated with extracellular protease
inhibitor (Fig. 3g, h), whereas in the group with intracel-
lular protease inhibitor, short collagen fibrils were
observed (Fig. 3f ). More obvious accumulation of long
collagen fibrils in groups with extracellular protease in-
hibitor was observed at 24 h (Fig. 3k, l). At high magnifi-
cations, the presence of elongated collagen fibrils within
the intracellular space was found in groups treated with
the extracellular protease inhibitor either in combination
with the intracellular protease inhibitor (Fig. 3m) or
alone (Fig. 3n-p). Moreover, internalized collagen co-
localized with lysosomes in the same focal plane
(Fig. 3m1 and 2, o1 and 2) at both 4 h (Fig. 3m, n) and
24 h (Fig. 3o, p). In separate experiments, quantitative
analysis of collagen at the intracellular space was con-
ducted via total fluorescence measurement in the cell
lysates collected up to 50 h after discarding the extracel-
lular collagen via collagenase digestion (Fig. 3q-t). It was
noted that, in the group with extracellular protease in-
hibitor GM6001 alone, the quantity of collagen at the
intracellular space did not show obvious change over
time (Fig. 3t), even though collagen fibrils appeared lon-
ger. On the other hand, continuous increase in the total
amount of internalized collagen from approximately 1 ×
107 to 7 × 107 was noted in the control group (Fig. 3q)
and the groups with intracellular protease inhibitor
(Fig. 3r, s).
Ascorbic acid and protease inhibitors work together in
enhancing collagen fibril deposition
In the absence of vitamin C, when removing the extra-
cellularly deposited collagen fibrils by collagenase after a
brief exposure to exogenous collagen, internalized rat
collagen and newly synthesized human collagen were lo-
cated intracellularly (Fig. 4a-c) while no collagen fibrils
were deposited at the extracellular space (Fig. 4a-d).
Vitamin C is known to stimulate collagen matrix depos-
ition as revealed in Fig. 4e, where obvious collagen fibril
deposition was noted even though no exogenous colla-
gen was supplemented. Without exogenous supplemen-
tation of collagen, when intracellular protease inhibitor
ED64 (Fig. 4f ) or extracellular protease inhibitor
GM6001 (Fig. 4h) was co-supplemented with vitamin C,
more extensive collagen fiber meshwork was found, sug-
gesting that vitamin C works synergistically with prote-
ase inhibitors in enhancing collagen fibril synthesis and
deposition. Interestingly, there was little fibril deposition
when both intracellular and extracellular protease inhibi-
tors were used (Fig. 4g), suggesting that possible interac-
tions between the intracellular and the extracellular
protease inhibition pathways deserve further investiga-
tion. When exogenous collagen was supplemented to
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Fig. 3 (See legend on next page.)
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the culture medium, co-supplementation of either the
intracellular or the extracellular protease inhibitor and
vitamin C significantly increased the abundance of colla-
gen fibrils deposited in the extracellular space in all
groups (Fig. 4i-l), suggesting that vitamin C and protease
inhibitors provide the optimal condition in enhancing
ECM deposition in hMSCs. It is also noted that newly
synthesized human collagen type I was found at the
intracellular space (white stars) (Fig. 4i-l). It is also inter-
esting to note that almost all collagen fibrils deposited at
the extracellular space showed extensive co-localization
with the exogenously supplemented fluorescence-labeled
rat tail collagen and the newly synthesized human colla-
gen type I (Fig. 4i-l), suggesting that the supplemented
collagen was used as a template by hMSCs for matrix re-
modeling and deposition.
Discussion
Here we report the interactions between collagen bioma-
terials and hMSCs and a method to promote extracellu-
lar collagen matrix deposition, therefore contributing to
better scaffolding for hMSC-based tissue engineering
and regenerative medicine. Upon exposure to exogen-
ously supplemented collagen biomaterials, hMSCs inter-
nalized collagen and degraded them intracellularly.
Three known pathways are involved in collagen turn-
over: (1) cleavage of collagen extracellularly by a group
of secreted or membrane-associated MMPs [1], (2)
Fig. 4 Collagen fibril deposition by hMSCs with and without exogenously supplemented collagen or ascorbic acid or both. a-d Immunofluorescence
staining of exogenous type I collagen (rat) and newly synthesized type I collagen (human) in hMSCs without ascorbic acid but with exogenously
supplemented collagen: a Merged channels. b Rat type I collagen. c Human type I collagen. d Nuclei. e-h Immunofluorescence staining of collagen
type I in hMSCs with ascorbic acid but without exogenously supplemented collagen. i-l Immunofluorescence staining of human type I collagen and
fluorescence-labeled exogenous rat type I collagen when vitamin C and exogenous collagen were co-supplemented. e, i Control. f, j Intracellular
protease inhibitor E64D. g, k Combination of intracellular (E64D) and extracellular (GM6001) protease inhibitors. h, l Extracellular protease
inhibitor GM6001. For (e-l), green: human type I collagen; red: Exogenously supplemented fluorescence-labeled rat tail collagen type I;
blue: 4ʹ,6-diamidino-2-phenylindole (DAPI). hMSC human mesenchymal stem cell
(See figure on previous page.)
Fig. 3 Intracellular collagen fibril formation and growth by hMSCs in different groups at different time points after removal of extracellular
collagen fibrils by treatment with bacterial collagenase type VI. a-p Visualization of internalized collagen after collagenase treatment. a-d 2 h.
e-h, m, n 4 h. i-l 6 h. o, p 24 h. a, e, i Control. b, f, j Inhibition of intracellular matrix degradation by cysteinase inhibitor (E64D). c, g, k, m
Combination of both intracellular (E64D) and extracellular (GM6001) protease inhibitors. d, h, l, n-p Inhibition of extracellular matrix degradation
by broad-spectrum protease inhibitor (GM6001). m 1–2, o1-2 Side views of hMSCs showing that the location of the stained fibrils was within the
intracellular space. q-t Quantitative measurement of total fluorescence intensity of internalized collagen per cell on images at 63× (mean + standard
deviation, n = 2 to 8). q Control. r Inhibition of intracellular matrix degradation by cysteine proteinase inhibitor (E64D). s Combination of both intracellular
(E64D) and extracellular (GM6001) protease inhibitors. t Inhibition of extracellular matrix degradation by broad-spectrum protease inhibitor (GM6001).
Green: Alexa Fluor 488-labeled collagen type I; orange: lysozyme; red: Plasma membrane; and grey: reflection. Collagen (10 mg/ml), E64D (20 μM), and
GM6001 (25 μM) were used. hMSC human mesenchymal stem cell
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cathepsin-mediated pathway [21], and (3) involvement of
collagen fibrils binding to specific cell surface receptors
followed by cellular internalization and lysosomal break-
down [24]. Previous studies have shown that phagocytosis
of collagen is initiated by binding through α2β1 integrin
receptors [25] or mediated by urokinase plasminogen acti-
vator receptor-associated protein (uPARAP/Endo180) [26]
or both. hMSCs may involve the first and the third path-
ways to regulate collagen turnover. Our in-house studies
showed that hMSCs expressed integrin α2β1 at the cell-
collagen matrix interface (Additional file 1), which is
known to mediate collagen internalization, as well as
MMPs, including MMP1, the major collagenase degrad-
ing collagen matrix (Additional file 2), and MT1-MMP
(Additional file 3), which is required to cleave collagen
extracellularly before collagen can be internalized
through the Endo180 pathway. Collagen internalization
is a spontaneous and time-dependent response when
cells such as fibroblasts are exposed to exogenous colla-
gen. This phenomenon has been shown to be independ-
ent of MMPs and cysteine proteases in fibroblasts [27, 28].
Similarly, hMSCs are able to internalize collagen in all
groups. The control group and those with intracellular
protease inhibitors exhibited the time-dependent in-
crease in the amount of internalized collagen, echoing
the protease-independent collagen uptake and internal-
ization [27, 28]. Interestingly, in the presence of the
extracellular protease inhibitors, the amount of internal-
ized collagen was maintained at a similar level through-
out the incubation period, suggesting that the enhanced
collagen fibril deposition at the extracellular space
should be a result of enhanced inhibition of matrix deg-
radation or increased export of collagen fibrils into the
extracellular space.
Our working hypothesis is to inhibit protease-based
collagen degradation so as to enhance the deposition of
extracellular collagen matrix, which is an important step
during matrix remodeling when hMSCs are in contact with
collagen biomaterials. E64D is a membrane-permeable
cysteine protease inhibitor, whereas GM6001 is a broad-
spectrum extracellular inhibitor of MMPs. Indeed, we
demonstrated that blockage of matrix proteases, particu-
larly the extracellular ones, induced and enhanced colla-
gen fibril deposition and accumulation, probably by (1)
reducing matrix degradation or (2) enhancing intracellular
and extracellular fibril formation and growth or both.
Creemers et al. [29] demonstrated that collagen degrad-
ation was strongly reduced in periosteal tissue explants as
a result of the inhibition of cysteine proteases or MMPs.
Reduction of collagen degradation was accompanied by an
accumulation of intracellular fibrillar collagen and de-
creased degradation of internalized collagen in fibroblasts
treated with cysteine protease inhibitor [30]. Hao et al.
[31] reported that GM6001 reduced collagen degradation
by inhibiting both the activation of pro-MMPs and the ac-
tivity of MMPs in keratocytes. We did demonstrate that
increased intracellular and extracellular fibril formation
and growth were observed, particularly in the GM6001
group, suggesting that this might be one of the mecha-
nisms of the enhanced fibril deposition at the extracellular
space. The presence of protease inhibitor but not the col-
lagen internalization/degradation is crucial in facilitating
the extracellular fibril deposition. This is because there
was very little extracellular collagen fibril deposition when
MSCs were exposed to exogenous collagen without prote-
ase inhibitors where we did see internalization and deg-
radation (Fig. 4a-c) whereas extracellular collagen fibril
deposition was seen only in the presence of protease in-
hibitors particularly the extracellular one (Fig. 4i-l).
Ascorbic acid is an essential cofactor for two enzymes
involved in post-translational modifications of collagen
[32] and increases collagen production [33, 34]. Fer-
nandes et al. [35] demonstrated that the amount of col-
lagen synthesized by hMSCs was decreased in the
absence of ascorbic acid. This observation is in line with
our data that little extracellular collagen fibril deposition
was found in the absence of ascorbic acid but that fibril
deposition was found in the presence of ascorbic acid
with and without supplementation of exogenous colla-
gen. It is evident that collagen degradation is stimulated
whenever collagen expression and deposition are en-
hanced. For example, Shiga et al. [36] showed that ascor-
bic acid increased collagen type I expression but in the
mean time induced the expression of collagenase-1 and
hence collagen degradation. Ruangpanit et al. [37] re-
ported that the fibrillar form of collagen induced MT1-
MMP expression and MMP-2 activation in fibroblasts.
In addition, Ishikawa et al. [38] demonstrated that vita-
min C enhanced the expression of α2β1 integrin, which
stimulated collagen internalization and degradation [25].
In the presence of protease inhibitor, particularly the
extracellular one (GM6001), the collagen degradation in-
duced by the presence of vitamin C is likely to be inhib-
ited, thereby enhancing extracellular deposition of
collagen fibrils. The extensive deposition of collagen fi-
brils is likely to be the result of the actions of both the
vitamin C-mediated enhancement in collagen binding
and post-translation of collagen as well as the protease
inhibitor-mediated reduction in collagen degradation.
Our study highlights the complexity of matrix remod-
eling of hMSCs and the fact that manipulation of matrix
proteases not only affects the matrix degradation but
also influences matrix deposition. Whether this ap-
proach, manipulation of matrix degradation through
treatment with different protease inhibitors, can be used
to promote ECM deposition during MSC-based tissue
engineering and regenerative medicine warrants further
investigations, but we do have some evidence on the
Han et al. Stem Cell Research & Therapy  (2015) 6:197 Page 9 of 11
effects of collagen internalization, degradation, and pro-
tease inhibitor treatments on MSC self-renewal and dif-
ferentiation potential. Specifically, internalization and
degradation of collagen when MSCs are in contact with
collagen are inevitable. It is likely that internalization
and degradation do not significantly affect MSC self-
renewal and differentiation. In our early study on the
collagen encapsulation process [2], during which MSCs
internalize collagen as shown in the present study
(Fig. 1g-i), when MSCs were allowed to migrate out
from the collagen matrix, their self-renewal capability
and multiple differentiation potential were not affected
at all [2]. Our lab has ongoing efforts in studying
whether supplementation of protease inhibitors will
affect differentiation of MSCs. Preliminarily, the addition
of protease inhibitors does affect chondrogenic differen-
tiation by shifting toward the formation of fibrocartilage
rather than hyaline cartilage (private communication).
Conclusions
The present study describes the interactions between
human MSCs and exogenously supplemented collagen.
This work demonstrates that ECM deposition can be
enhanced by inhibition of protease matrix degradation.
Upon exposure to collagen, hMSCs internalize and de-
grade collagen. In the presence of protease inhibitors,
intracellular collagen fibril growth was noted while
extracellular collagen fibril deposition was enhanced.
The presence of ascorbic acid in addition to protease
inhibitors further enhanced the deposition and accu-
mulation of collagen fibrils at the extracellular space.
This study provides better understanding on the inter-
actions between hMSCs and collagen biomaterials and
suggests a method to manipulate matrix remodeling
and collagen deposition of hMSCs, contributing to bet-
ter scaffolding for tissue engineering and regenerative
medicine.
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